Indoco Remedies arm launches heart attack drug Ticagrelor filmcoated in UK

“This development underscores our commitment to bringing high quality, life-saving treatments to patients in the UK”, said Aditi Kare Panandikar, Managing Director, Indoco Remedies Ltd.

Read also: Indoco Remedies Varenicline Tablets gets USFDA nod to aid smoking cessation treatment

Indoco is a fully integrated, research-oriented pharmaceutical company with a global presence. The Company’s turnover is US$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff. The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties.

Read also: Indoco Remedies enters into distribution partnership with Clarity Pharma

Indoco has 10 domestic marketing divisions, a brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, CitalUti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

Read also: Indoco Remedies secures USFDA approval for Allopurinol Tablets to lower high uric acid levels in blood